Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Glenmark Life Sciences — Non-Deal Roadshow (March 2024)
10 slides from Alivus Life Sciences's roadshow presentation, Mar 11, 2024
Slide 1: Regulation 30 disclosure letter – Investors Presentation
11th March, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Glenmark Life Sciences (GLS)
Glenmark Life Sciences (GLS) G Glenmark LIFE SCIENCES
Slide 3: GLS Background
GLS Background GLS is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providin
Slide 4: Manufacturing and R&D Platform
Manufacturing and R&D Platform Multi-purpose Manufacturing Facilities Manufacturing Core Competencies ► US FDA inspected: Ankleshwar, Dahej and Mohol ► Multi purpose plants allow high asset utilization ► Plants have reactors ranging from 50 L to Portfolio driven by non 742 KL Ankleshwar 16,000 L c
Slide 5: Wide Global Footprint
75+ 700+ Wide Global Footprint Countries Customers Regulated Markets Emerging Markets India - Mix of Regulated and Emerging 70+ ROW 97 370+ 30+ Number of Customers 126 Serviced in 9MFY24 160 10+ Number of 18 DMF/CEP Filings as of 9MFY24 125+ 502 10+ Filed 502 DMFs and CEPs 50+ 22 across major market
Slide 6: Well Diversified Business
Well Diversified Business 146 Portfolio of Diversified Molecules 20 Largest generics companies of the world are our customers 75% Business is from repeat customers since 2019 Revenue Break-up North America 11% Emerging Markets 22% Latam 16% 2023 Japan Europe 6% 22% India 24% 5
Slide 7: Broader Portfolio reduces dependence on Top APIs
Broader Portfolio reduces dependence on Top APIs Chronic Vs Acute Key Therapeutic areas 6
Slide 8: Financial Highlights
Financial Highlights Revenue (₹m) EBITDA (₹m) PAT (₹m) 21.6% 31.5% 31.4% 31.1% 31.0% 21.4% 21,612 30.6% 20.8% 20.4% 21,232 29.7% 19.7% 18.6% 4,670 18,852 17,466 6,712 4,187 6,308 15,373 3,730 5,919 14,050 3,516 5,417 3,131 4,840 2,927 4,298 FY19 FY20 FY21 FY22 FY23 9MFY24 FY19 FY20 FY21 FY22 FY23 9M
Slide 9: Financial Highlights
Financial Highlights ₹ millions 2019 2020 2021 2022 2023 9MFY24 Income Statement Revenue from Operations EBITDA for the year Profit for the year Basic EPS 14,050 4,298 2,927 27.1 15,373 4,840 3,131 29.0 18,852 5,919 3,516 32.6 21,232 6,308 4,187 35.6 21,612 6,712 4,670 38.1 17,466 5,417 3,730 30.4 4
Slide 10: Outlook
Outlook Mid-Teens CDMO – To Growth Double by 2027 Stable Stable Cash Flow Margins to fund the Capex Industry Leading Dividend Payout 9
Glenmark Life Sciences — Non-Deal Roadshow (March 2024) on 6ix